# Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

> **NCT00397800** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Technical University of Munich** · enrollment: 12 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **RADIATION:** yttrium Y 90 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT00397800
- **Lead sponsor:** Technical University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-06
- **Primary completion:** 2008-05
- **Final completion:** 2013-05
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2012-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00397800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00397800, "Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00397800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*